Leaky Vaccines: A Wicked Problem in Accelerated Vaccine Development

Janice Graham; Koen Peeters Grietens

doi:10.18357/anthropologica66120242649

Authors

Janice Graham https://orcid.org/0000-0002-6326-8122
Koen Peeters Grietens Institute of Tropical Medicine and Nagasaki University

DOI:

https://doi.org/10.18357/anthropologica66120242649

Abstract

While no vaccine can provide 100 percent protection, a high standard of regulatory safety, efficacy and quality is essential for public trust and the uptake of vaccines as essential global public health tools. This article addresses a growing concern that suboptimal “leaky” vaccines threaten emergency response to pandemics as well as routine public health programs. Agile regulatory standards now advance earlier approval of vaccines and therapeutics that may have suboptimal effectiveness. The benefit-harm trade- offs that play an enormous role in regulatory assessment and all stages of vaccine development and delivery deserve better public scrutiny, transparency, and accountability. Drawing on the case of the first licensed malaria vaccine, RTS,S Mosquirix™, in light of the rapid approval of COVID-19 vaccines, we consider the socio-technical implications of leaky vaccines in global vaccine logics and suggest possibilities for building legitimacy to inform the next generation of regulatory technology policy.

Downloads

Download data is not yet available.

References

Agarwal, Ritu, Michelle Dugas, and Jui Ramaprasad. 2021. “Socioeconomic Privilege and Political Ideology are Associated with Racial Disparity in COVID-19 Vaccination.” Proceedings of the National Academy of Sciences 118 (33) e2107873118. https://doi.org/10.1073/pnas.2107873118.

Albrecht, Don. 2022. “Vaccination, Politics and COVID-19 Impacts.” BMC Public Health 14 22(1): 96. https://doi.org/10.1186/s12889-021-12432-x.

Alghounaim, Mohammad, Zainab Alsaffar, Abdulla Alfraij, Saadoun Bin-Hasan, and Entesar Hussain. 2022. “Whole-Cell and Acellular Pertussis Vaccine: Reflections on Efficacy.” Medical Principles and Practice 31 (4): 313–321. https://doi.org/10.1159/000525468.

Ashepet, Mercy G., Liesbet Jacobs, Michiel Van Oudheusden, and Tina Huyse. 2021. “Wicked Solution for Wicked Problems: Citizen Science for Vector-Borne Disease Control in Africa.” Trends in Parasitology 37(2): 93-96. https://doi.org/10.1016/j.pt.2020.10.004.

Azuma, Kentaro. 2015. “Regulatory Landscape of Regenerative Medicine in Japan.” Current Stem Cell Reports 1: 118–128. https://doi.org/10.1007/s40778-015-0012-6.

Bardosh K., A. de Figueiredo, R. Gur-Arie, E. Jamrozik, J. Doidge, T. Lemmens, S. Keshavjee, J.E. Graham, and S. Baral. 2022. “The Unintended Consequences of COVID-19 Vaccine Policy: Why Mandates, Passports, and Restrictions May Cause More Harm than Good.” BMJ Global Health. https://gh.bmj.com/content/bmjgh/7/5/e008684.full.pdf.

Björkman, Anders, Christine Stabell Benn, Pater Aaby, Allan Schapira. 2023. “RTS,S/ AS01 Malaria Vaccine -Proven Safe and Effective?” Lancet Infectious Disease 23 (8) e318-e322. https://doi.org/10.1016/S1473-3099(23)00126-3.

Bothwell, L.E., J.A. Greene, S.H. Podolsky, and D.S. Jones. 2016. “Assessing the Gold Standard—Lessons from the History of RCTs.” New England Journal of Medicine 374(22): 2175–2181. https://www.nejm.org/doi/10.1056/NEJMms1604593. (Accessed 29 August 2024).

Brende, B., J. Farrar, D. Gashumba, C. Moedas, T. Mundel, Y. Shiozaki, H. Vardhan, J. Wanka, and J.A. Røttingen. 2017. “CEPI—A New Global R and D Organisation for Epidemic Preparedness and Response.” Lancet 389(10066): 233–235. https://doi.org/10.1016/S0140-6736(17)30131-9

Broutin, Hélène, O. Thiongane, L. Agier, I. Van-Engelgem, J.-P. Jemmy Ghomsi, A. Ouattara, M. Doutchi, H.B. Manassara, A.T. Dia, and J. E. Graham. 2018. “Fighting Meningitis in Africa: A Call for a Multi-Sectorial Action.” Journal of Tropical Medicine and Health. JTMH-129. https://www.gavinpublishers.com/article/view/fighting-meningitis-in-africa-a-call-for-a-multi-sectorial-action.

Butler, D. 2017. “Billion-Dollar Project aims to prep Vaccines before Epidemics Hit.” Nature. 26 January; 541(7638): 444–445. https://doi.org/10.1038/nature.2017.21329.

Centers for Disease Control and Prevention (CDC). 2021. Vaccines. https://web.archive.org/web/20200831141506/https://www.cdc.gov/malaria/malaria_worldwide/reduction/vaccine.html. (Accessed 29 August 2024).

——. 2023. “Rotavirus Vaccine (RotaShield®) and Intussusception.” https://www.cdc.gov/vaccines/vpd-vac/rotavirus/vac-rotashield-historical.htm. (accessed 3 June 2023).

——. 2024. Malaria Vaccines. https://www.cdc.gov/malaria/php/public-health-strategy/malaria-vaccines.html (Accessed 29 August 2024).

Chandramohan, Daniel, Issaka Zonga, Issaka Sagara, Matthew Cairms, et al. 2021. “Seasonal Malaria Vaccination with or without Seasonal Malaria Chemoprevention.” The New England Journal of Medicine 25 August. 385:1005–1017. https://doi.org/10.1056/NEJMoa2026330.

Clark, Andrew, Jacqueline Tate, Umesh Parashar, Mark Jit, M. Hasso-Agopsowicz, N. Henschke, B. Lopman B, K.Van Zandvoort, C. Pecenka, P. Fine, and C. Sanderson. 2019. “Mortality Reduction Benefits and Intussusception Risks of Rotavirus Vaccination in 135 Low-Income and Middle-Income Countries: A Modelling Analysis of Current and Alternative Schedules.” Lancet Global Health. November 7(11): e1541-e1552. https://doi.org/10.1016/S2214-109X(19)30412-7.

Coleho, C. H., J.Y.A. Doritchamou, I. Zaidi, and P.E. Duffy. 2017. “Advances in Malaria Vaccine Development: Report from the 2017 Malaria Vaccine Symposium.” NPJ Vaccines 2 (34) https://doi.org/10.1038/s41541-017-0035-3.

Dabira, E. D., H.M. Soumare, H.B. Conteh, F. Ceesay, M.O. Ndiath, J. Bradley, N. Mohammed, B. Kandeh, M. R. Smit, H. Slater, K. Peeters Grietens, H. Broekhuizen, T. Bousema, C. Drakeley, S.W. Lindsay, J. Achan and U. D’Alessandro. 2022. “Mass Drug Administration of Ivermectin and Dihydroartemisinin-Piperaquine against Malaria in Settings with High Coverage of Standard Control Interventions: A Cluster-Randomised Controlled Trial in The Gambia.” Lancet Infectious Diseases, 22(4): 519–528. https://doi.org/10.1016/S1473-3099(21)00557-0.

Datoo, MS., H.M. Natama, A. Somé, O. Traoré, T. Rouamba, D. Bellamy, et al. 2021. “Efficacy of a Low-Dose Candidate Malaria Vaccine, R21 in Adjuvant Matrix-M, with Seasonal Administration to Children in Burkina Faso: A Randomized Controlled Trial.” The Lancet 397 (10287):1809–1818. https://doi.org/10.1016/S0140-6736(21)00943-0.

Datoo, M.S., H.M. Natama, A. Somé, D. Bellamy, O. Traoré, T. Rouamba, et al. 2022. “Efficacy and Immunogenicity of R21/Matrix-M Vaccine Against Clinical Malaria after 2 Years’ Follow-up in Children in Burkina Faso: a Phase 1/2b Randomized Controlled Trial.” The Lancet Infectious Diseases 22(12):1728–1736. https://doi.org/10.1016/S1473-3099(22)00442-X.

Dinga, J.N., S.D. Gamua, S.M. Ghogomu, V.P.K. Titanji. 2018. “Preclinical Efficacy and Immunogenicity Assessment to show that a Chimeric Plasmodium Falciparum UB05-09 Antigen could be a Malaria Vaccine Candidate.” Parasite Immunology 40(3): e12514. https://doi.org/10.1111/pim.12514.

Doshi, Peter. 2020. “Will COVID-19 Vaccines Save Lives? Current Trials aren’t designed to tell us.” British Medical Journal 371: m4037. https://doi.org/10.1136/bmj.m4037.

Douglas, Mary. 1970. Natural Symbols: Explorations in Cosmology. New York: Pantheon Books.

Douglas, Mary and Aaron Wildavsky. 1982. Risk and Culture: An Essay on the Selection of Technical and Environmental Dangers. Berkeley: University of California Press.

Edmonds, Sterling, Andrea MacGregor, Agnieszka Doll, Ipek Eren Vural, Janice Graham, Katherine Fierlbeck, Joel Lexchin, Peter Doshi, and Matthew Herder. 2020. “Transparency too little, too late? Why and how Health Canada should make Clinical Data and Regulatory Decision-Making Open to Scrutiny in the Face of COVID-19.” Journal of Law and the Biosciences 7 (1) January-June 2020, lsaa083, https://doi.org/10.1093/jlb/lsaa083.

El Zarrad, M. Khair, Aaron Y. Lee, Rose Purcell, and Scott J. Steele. 2022. “Advancing an Agile Regulatory Ecosystem to Respond to the Rapid Development of Innovative Technologies.” Clinical and Translational Science 15(6): 1332–1339. https://doi.org/10.1111/cts.13267.

European Medicines Agency (EMA) 2015. “First Malaria Vaccine Receives Positive Scientific Opinion from EMA.” https://www.ema.europa.eu/en/news/first-malaria-vaccine-receives-positive-scientific-opinion-ema. (accessed 3 June 2023).

Fehr, A., C. Nieto-Sanchez, J. Muela, F. Jaiteh, O. Ceesay, E. Maneh, and K. Peeters Grietens. 2021. “From Informed Consent to Adherence: Factors Influencing Involvement in Mass Drug Administration with Ivermectin for in The Gambia.” Malaria Journal 20(1), [198]. https://doi.org/10.1186/s12936-021-03732-z.

Fraiman, J. J., M. Erviti, S. Jones, P. Greenland, P. Whelan, R.M. Kaplan, P. Doshi. 2022. “Serious Adverse Events of Special Interest Following mRNA COVID-19 Vaccination in Randomized Trials in Adults.” Vaccine 40 (40):5798–5805. https://doi.org/10.1016/j.vaccine.2022.08.036.

Franco-Paredes, Carlos. 2022. “Transmissibility of SARS-CoV-2 Among Fully Vaccinated Individuals.” Lancet Infectious Diseases 22(1):16. https://doi.org/10.1016/S1473-3099(21)00768-4.

Gavi. 2023. “Five Things you Need to Know About the New R21 Malaria Vaccine.” https://www.gavi.org/vaccineswork/five-things-you-need-know-about-new-r21-malaria-vaccine (accessed 3 June 2023).

Goddard-Borger, Ethan D. and Justin A. Boddey. 2018. “Implications of Plasmodium Glycosylation on Vaccine Efficacy and Design.” Future Microbiology 13 (6): 609–612. https://doi.org/10.2217/fmb-2017-0284.

Good, Byron. 1993. Medicine, Rationality and Experience. Cambridge: Cambridge University Press.

Good, Michael F. and Louis H. Miller. 2018. “Interpreting Challenge Data from Early Phase Malaria Blood Stage Vaccine Trials.” Expert Review of Vaccines 17 (3):189–196. https://doi.org/10.1080/14760584.2018.1435278.

Goodman, Jesse L, John D. Grabenstein, and M. Miles Braunn. 2020. “Answering Key Questions About COVID-19 Vaccines.” Journal of the American Medical Association 324 (20): 2027–2028. https://doi.org/10.1001/jama.2020.20590.

Graham, J.E. 2016. “Ambiguous Capture: Collaborative Capitalism and the Meningitis Vaccine Project.” Medical Anthropology: Cross-Cultural Studies in Health and Illness 35 (5): 419–432. https://doi.org/10.1080/01459740.2016.1167055.

Graham, J.E. 2019. “Ebola vaccine innovation: a Case Study of Pseudoscapes in Global Health.” Critical Public Health 29 (4):401–412. https://doi.org/10.1080/09581596.2019.1597966.

Graham J.E., A. Borda-Rodrigeuz, F. Huzair, and E. Zinck. 2012. “Capacity for a Global Vaccine Safety System: The Perspective of National Regulatory Authorities.” Vaccine, 30(33): 4953–4959. https://doi.org/10.1016/j.vaccine.2012.05.045.

Greenwood, Brian. 2021. Vaccine Decision Marks Historic Moment in Malaria Control. https://www.lshtm.ac.uk/newsevents/news/2021/vaccine-decision-marks-historic-moment-malaria-control (accessed 3 June 2023).

Gryseels, C., S. Uk, V. Sluydts, L. Durnez, P. Phoeuk, S. Suon, S. Set, S. Heng, S. Siv, R. Gerrets, S. Tho, M. Coosemans, and K. Peeters. 2015. “Factors Influencing the Use of Topical Repellents: Implications for the Effectiveness of Malaria Elimination Strategies.” Scientific Reports 5 (16847). https://doi.org/10.1038/srep16847.

Gryseels, C., S. Uk, A. Erhart, R. Gerrets, V. Sluydts, L. Durnez, J. Muela Ribera, S. Hausmann Muela, D. Menard, S. Heng, T. Sochantha, U. D’Alessandro, M. Coosemans, and K. Peeters Grietens. 2013. “Injections, cocktails and diviners: therapeutic flexibility in the context of malaria elimination and drug resistance in northeast Cambodia.” PLOS ONE, 8 (11): e80343. https://doi.org/10.1371/journal.pone.0080343.

Gryseels, C., M. Bannister-Tyrrell, S. Uk, S. Set, S. Sokha, R. Gerrets, and Peeters Grietens, K. 2019. “A Critical Enquiry into Variability of Insecticidal Net Use in Cambodia: Implications for Assessing Appropriateness of Malaria Elimination Interventions.” American Journal of Tropical Medicine and Hygiene. 100 (6): 1424–1432. https://doi.org/10.4269/ajtmh.18-0730.

GSK. 2016. “Our Commitment to Fighting Malaria.” https://www.gsk.com/media/2534/malaria-factsheet-23-feb-2016.pdf (accessed 3 June 2023).

——. 2023a. “Our 30-year Quest for a Malaria Vaccine.” https://www.gsk.com/media/2212/malaria-timeline-full.pdf (accessed 3 June 2023).

——. 2023b. “Behind the science of GSK.” https://www.gsk.com/en-gb/behind-the-science/access-to-healthcare/why-are-we-fighting-malaria-in-the-lab-and-on-the-ground/ (accessed 3 June 2023).

Halloran ME, M. Haber, and I.M. Longini. 1992. “Interpretation and estimation of vaccine efficacy under heterogeneity.” American Journal of Epidemiology 136 (3): 328–343. https://doi.org/10.1093/oxfordjournals.aje.a116498.

Haber, M., L. Watelet, and M.E. Halloran. 1995. “On individual and population effectiveness of vaccination.” International Journal of Epidemiology 24 (6) :1249–1260. https://doi.org/10.1093/ije/24.6.1249.

Haraway, Donna J. 1996. Modest_Witness@Second_Millennium.FemaleMan©_Meets_OncoMouse™. Feminism and Technoscience. New York and London: Routledge.

Head, B. 2008. “Wicked Problems in Public Policy.” Public Policy 3(2):110–118. Health Justice Initiative. 2023. https://healthjusticeinitiative.org.za/. (accessed 3 June 2023).

Iglesias-López, Carolina, Antonia Agustí, Mercè Obach, and Antonio Vallano. 2019. “Regulatory framework for advanced therapy medicinal products in Europe and United States.” Frontiers in Pharmacology 10: 921. https://doi.org/10.3389/fphar.2019.00921

Infectious Prevention and Control Canada (IPAC). 2023. Coronavirus (COVID-19) SARS- CoV-2. https://ipac-canada.org/coronavirus-resources#:~:text=On%20May%204%2C%202023%2C%20the,of%20international%20concern%20(PHEIC). (Accessed 12 June 2023).

Jaiteh, F., Y. Masunaga, J. Okebe, U. D’Alessandro, J. Balen, C. Gryseels, J. Muela Ribera, and K. Peeters Grietens. 2019. “Community Perspectives on Treating Asymptomatic Infections for Malaria Elimination in The Gambia.” Malaria Journal 18 (39). https://doi.org/10.1186/s12936-019-2672-7.

Jaiteh, Fatou, J. M. Ribera, Y. Masunaga, J. Okebe, U. D’Alessandro, J. Balen, and K. Peeters Grietens. 2021a. “Complexities in Defining the Unit of Intervention for Reactive Community-Based Malaria Treatment in the Gambia.” Frontiers in Public Health, 9 [601152]. https://doi.org/10.3389/fpubh.2021.601152

Jaiteh, F., J. Okebe, Y. Masunaga, U. D’Alessandro, J. Achan, C. Gryseels, and K. Peeters Grietens. 2021b. “Understanding Adherence to Reactive Treatment of Asymptomatic Malaria Infections in The Gambia.” Scientific Reports, 11(1), [1746]. https://doi.org/10.1038/s41598-021-81468-1.

Janssen M.A., and W. J. M. Martens. 1997. “Modeling Malaria as a Complex Adaptive System.” Artificial Life 3(3): 213–236. https://doi.org/10.1162/artl.1997.3.3.213.

Ioannidis, John P.A., Sally Cripps and Martin A. Tanner. 2022. “Forecasting for COVID- 19 has Failed.” International Journal of Forecasting 28(2): 423–438. https://doi.org/10.1016/j.ijforecast.2020.08.004.

Klein S. L., F. Shann, W. J. Moss, C. S. Benn, and P. Aaby. 2016. “RTS,S Malaria Vaccine and Increased Mortality in Girls.” mBio 7(2): e00514– e00516. https://doi.org/10.1128/mBio.00514-16.

Kupperschmidt, Kai. 2015. “Risk of ‘Leaky’ Vaccines Debated.” Science 349 (6247): 461–462. https://doi.org/10.1126/science.349.6247.461.

Lakoff, Andrew. 2007. “Are we Prepared for the Next Disaster?” Contexts 6(3): 10–12. https://doi.org/10.1525/ctx.2007.6.3.10.

Latour, Bruno. 1993. We Have Never Been Modern. Cambridge: Cambridge University Press.

Lauerman, John. 1988. “One Colombian’s Quest for a Malaria Vaccine.” The Scientist. https://www.the-scientist.com/news/one-colombians-quest-for-a-malaria-vaccine-62354 (accessed 3 June 2023).

Laurens, Matthew B. 2021. “Novel Malaria Vaccines.” Human Vaccines and Immunotherapeutics 17 (11): 4549–4552. https://doi.org/10.1080/21645515.2021.1947762.

Lock, Margaret, et Vinh-Kim Nguyen. 2011. An Anthropology of Biomedicine. 2 ed. Oxford: Wiley Blackwell.

Lundh, A., J. Lexchin, B. Mintzes, J.B. Schroll, and L. Bero. 2017. “Industry Sponsorship and Research Outcome.” Cochrane Database Systematic Review, 2 (2): MR000033. https://doi.org/10.1002/14651858.mr000033.pub3.

Malaria Vaccination Initiative. 2022. “PATH welcomes US$% million grant to expand malaria vaccine access in Ghana, Kenya, and Malawi.” PATH, 19 April. https://www.path.org/media-center/path-welcomes-us-5-million-grant-expand-malaria-vaccine-access-ghana-kenya-and-malawi/#:~:text=Seattle%2C%20April%2019%2C%202022%E2%80%94,Ghana%2C%20Kenya%2C%20and%20Malawi (accessed 3 June 2023).

Patarroyo, Manuel., R. Amador, R., P. Clavijo, Alberto Moreno, Fanny Guzman, Pedro Romero, Ricardo Tascon, Antonio Franco, Luis A. Murillo, Gabriel Ponton & Gustavo Trujillo. 1988. “A Synthetic Vaccine Protects Humans Against Challenge with Asexual Blood Stages of Plasmodium falciparum malaria.” Nature 332: 158–161. https://doi.org/10.1038/332158a0.

Märzhauser, Helene. 2018. “Risks of Dengue Vaccination.” Science, 2 July. http://www.dw.com/en/dengue-risks-and-side-effects-of-the-worlds-first-vaccine/a-42488407 (Accessed 3 June 2023).

Masunaga, Y., J. Muela Ribera, T. T. Nguyen., K. Tesfazghi, and K. Peeters Grietens. 2021. “In Search of the Last Malaria Cases: Ethnographic Methods for Community and private-sector Engagement in Malaria Elimination in Vietnam, Laos, and Cambodia.” Malaria Journal 20 (1): [370]. https://doi.org/10.1186/s12936-021-03903-y.

Masunaga, Y., F. Jaiteh, E. Manneh, J. Balen, J. Okebe, U. D’Alessandro, C. Nieto- Sanchez, D. H. de Vries, R. Gerrets, K. Peeters Grietens, and J. Muela Ribera. 2021. “The Community Lab of Ideas for Health: Community-Based Transdisciplinary Solutions in a Malaria Elimination Trial in The Gambia.” Frontiers in Public Health 9: [637714]. https://doi.org/10.3389/fpubh.2021.637714.

Morgan S., A. Hollis, C. McCabe, M. Herder, and M. Paulden. 2023. “Canada’s Misguided Changes to Drug Regulation Could Fast-Track Unproven Medications and Divert Funds From Other Health Needs.” The Conversation, 26 June. https://theconversation.com/canadas-misguided-changes-to-drug-regulation-could-fast-track-unproven-medications-and-divert-funds-from-other-health-needs-207463 (accessed 30 June 2023).

Moris, Philippe, Erik Jongert, and Robbert G. van der Most. 2018. “Characterization of T-cell Immune Responses in Clinical Trials of the Candidate RTS,S Malaria Vaccine.” Human Vaccines and Immunotherapies 14 (1): 17–27. https://doi.org/10.1080/21645515.2017.1381809.

Muela Ribera, J., S. Hausmann-Muela, C. Gryseels, and K. Peeters Grietens. 2016. “Re-imagining Adherence to Treatment from the ‘Other Side’: Local Interpretations of Adverse Anti-Malarial Drug Reactions in the Peruvian Amazon.” Malaria Journal, 15(136). https://api.semanticscholar.org/CorpusID:14703669. (Accessed 30 June 2023).

Muurlink, Olav T., and Andrew W Taylor-Robinson. 2020. “The ‘Lifecycle’ of Human Beings: A Call to Explore Vector-Borne Diseases from an Ecosystem Perspective.” Infectious Diseases of Poverty 9(1): 37. https://doi.org/10.1186/s40249-020-00653-y.

Nguyen, T. T., C. Gryseels, D. T. Tran, T. Smekens, R. Gerrets, X. X. Nguyen, and K. Peeters Grietens. 2021. “Understanding Malaria Persistence: A Mixed-Methods Study on the Effectiveness of Malaria Elimination Strategies in South-Central Vietnam.” Frontiers in Public Health, 9, [742378]. https://doi.org/10.3389/fpubh.2021.742378.

Nielsen CM., J. Vekemans, M. Lievens, K.E. Kester, J.A. Regules, and C.F. Ockenhousee. 2018. “RTS,S Malaria Vaccine Efficacy and Immunogenicity During Plasmodium Falciparum Challenge is Associated with HLA Genotype.” Vaccine 36(12):1637–1642. https://doi.org/10.1016/j.vaccine.2018.01.069.

Nlinwe, Nfor Omarine, Kwadwo Asamoah Kusi, Bright Adu, and Martha Sedegah. 2018. “T-cell Responses Against Malaria: Effect of Parasite Antigen Diversity and Relevance for Vaccine Development.” Vaccine 36(17): 2237–2242. https://doi.org/10.1016/j.vaccine.2018.03.023.

Olotu A., V Urbano, A. Hamad, M. Eka, M. Chemba, E. Nyakarungu, Jose Raso, Esther Eburi, Dolores O. Mandumbi, Dianna Hergott, Carl D. Maas, Mitoha O. Ayekaba, Diosdado N. Milang, Matilde R. Rivas, Tobias Schindler, Oscar M. Embon, Adam J. Ruben, Elizabeth Saverino, Yonas Abebe, Natasha KC, Eric R. James, Tooba Murshedkar, Anita Manoj, Sumana Chakravarty, Minglin Li, Matthew Adams, Christopher Schwabe, J. Luis Segura, Claudia Daubenberger, Marcel Tanner, Thomas L. Richie, Peter F. Billingsley, B. Kim Lee Sim, Salim Abdulla, and Stephen L. Hoffman. 2018. “Advancing Global Health through Development and Clinical Trials Partnerships: A Randomized, Placebo-Controlled, Double-Blind Assessment of Safety, Tolerability, and Immunogenicity of PfSPZ Vaccine for Malaria in Healthy Equatoguinean Men.” American Journal of Tropical Medicine and Hygiene 98 (1): 308–318. https://doi.org/10.4269/ajtmh.17-0449.

O’Ryan, Miguel. 2017. “Rotavirus Vaccines: A Story of Success with Challenges Ahead.” F1000 Research 18(6): 1517. https://doi.org/10.12688/f1000research.11912.1.

Osterholm, M. T., N. S. Kelley, J. M. Manske, K. S. Ballering, T. R. Leighton, and K. A. Moore. 2012. The Compelling Need for Game-Changing Influenza Vaccines: An Analysis of the Influenza Vaccine Enterprise and Recommendations for the Future. Center for Infectious Diseases Research and Policy (CIDRAP) Report. Minneapolis, MN: University of Minnesota. http://www.cidrap.umn.edu/sites/default/files/public/downloads/ccivi_report.pdf. (Accessed 30 June 2023).

Otto S.P., T. Day, J. Arino, C. Colijn, J. Dushoff, M. Li, S. Mechai, G.V. Domselaar, J. Wu, D.J.D. Earn, and N.H. Ogden. 2021. “The Origins and Potential Future of SARS- CoV-2 Variants of Concern in the Evolving COVID-19.” Current Biology 31 (14): PR918–929. https://doi.org/10.1016/j.cub.2021.06.049.

Patarroyo, M., R. Amador, P. Clavijo, A. Moreno, F. Guzzman, P. Romero, R. Tascon., Antonio Franco, Luis A. Murillo, Gabriel Ponton and Gustavo Trujillo. 1988. “A Synthetic Vaccine Protects Humans Against Challenge with Asexual Blood Stages of Plasmodium falciparum malaria.” Nature 332: 158–161. https://doi.org/10.1038/332158a0.

Peeters Grietens, K., X. Nguyen Xuan, J. Muela Ribera, T. Ngo Duc, W. Van Bortel, N. Truong Ba, K.P. Van, H. Le Xuan, U. D’Alessandro, and A. Erhart. 2012. “Social Determinants of Long-Lasting Insecticidal Hammock-Use Among the Ra-Glai Ethnic Minority in Vietnam: Implications for Forest Malaria Control.” PLOS ONE 7(1): e29991. https://doi.org/10.1371/journal.pone.0029991.

Peeters Grietens, K., J. Muela Ribera,, V. Soto, A. Tenorio, S. Hoibak, A.R. Aguirre, E. Toomer, H. L. K. Rodriguez., A. Llanos Cuentas, U. D’Alessandro, D. Gamboa, and A. Erhart. 2013. “Traditional Nets Interfere with the Uptake of Long-Lasting Insecticidal Nets in the Peruvian Amazon: The Relevance of Net Preference for Achieving High Coverage and use.” PLOS ONE 8(1): e50294. https://doi.org/10.1371/journal.pone.0050294.

Peeters Grietens, K., C. Gryseels, S. Dierickx, M. Bannister-Tyrrell, S. Trienekens, S. Uk., P. Phoeuk, S. Suon, S. Set, R. Gerrets, S. Hoibak, J. Muela Ribera S. Hausmann-Muela, S. Tho, L. Durnez, V. Sluydts, U. D’Alessandro, M. Coosemans, and A. Erhart. 2015. “Characterizing Types of Human Mobility to Inform Differential and Targeted Malaria Elimination Strategies in Northeast Cambodia.” Scientific Reports 5: 16837. https://doi.org/10.1038/srep16837.

Peeters Grietens, K., C. Gryseels, and G. Verschraegen 2019. “Misdirection in the Margins of the Methods of the Malaria Elimination Paradigm.” Critical Public Health. https://doi.org/10.1080/09581596.2019.1597965.

Peng, Yilang. 2022. “Politics of COVID-19 Vaccine Mandates: Left/right-wing Authoritarianism, Social Dominance Orientation, and Libertarianism.” Personality and Individual Differences 194: 111661. https://doi.org/10.1016/j.paid.2022.111661.

Proper, Olivia, Nick Ruktanonchai and Maia Martcheva. 2014. “Optimal Vaccination and Bednet Maintenance for the Control of Malaria in a Region with Naturally Acquired Immunity.” Journal of Theoretical Biology 353(21): 142–156. https://doi.org/10.1016/j.jtbi.2014.03.013.

Prugger, C., A. Spelsberg, U. Keil, J. Erviti, and P. Doshi. 2021. “Evaluating COVID-19 Vaccine Efficacy and Safety in the Post-Authorisation Phase.” British Medical Journal 375. https://doi.org/10.1136/bmj-2021-067570.

Read, A.F., S.J. Baigent, C. Powers, L.B. Kgosana, L. Blackwell, L.P. Smith, David A. Kennedy, Stephen W. Walkden-Brown, and Venugopal K. Nair. 2015. “Imperfect Vaccination Can Enhance the Transmission of Highly Virulent Pathogens.” PLOS Biology 13(7): e1002198. https://doi.org/10.1371/journal.pbio.1002198

Ross, A. 2017. “Vaccination Alone will not halt the Next Global Pandemic.” BMJ Opinion. http://blogs.bmj.com/bmj/2017/06/09/allen-ross-vaccination-alone-will-not-halt-the-next-global-pandemic/ (accessed 30 June 2023).

Røttingen J.A, D. Gouglas, M. Feinberg, S. Plotkin, K.V. Raghavan, A. Witty, R. Draghia- Akli, P. Stoffels, and P. Piot. 2017. “New Vaccines Against Epidemic Infectious Diseases.” New England Journal of Medicine 376 (7): 610–613. https://doi.org/10.1056/NEJMp1613577.

RTS,S Clinical Trials Partnership. 2012. “First Results of Phase 3 Trial of RTS,S/AS01 Malaria Vaccine in African Infants.” New England Journal of Medicine 365(20): 1863– 1875. https://doi.org/10.1056/NEJMoa1102287.

——. 2014. “Efficacy and Safety of the RTS,S/AS01 Malaria Vaccine during 18 Months after Vaccination: A Phase 3 Randomized, Controlled Trial in Children and Young Infants at 11 African Sites.” PLOS Medicine 29 July. https://doi.org/10.1371/journal.pmed.1001685.

——. 2015. “Efficacy and Safety of the RTS,S/AS01 Malaria Vaccine With or Without a Booster Dose in Infants and Children in Africa: Final Results of a Phase 3, Individually Randomized Clinical Trial. The Lancet 386 (9988): 31–45. https://doi.org/10.1016/S0140-6736(15)60721-8.

Ryan, Molly, Tamara Giles-Vernick, and Janice E. Graham. 2019. “Technologies of Trust in Epidemic Response: Openness, Reflexivity and Accountability During the 2014- 2016 Ebola Outbreak in West Africa.” BMJ Global Health 2019(4): e001272 https://gh.bmj.com/content/4/1/e001272.

Schwartz K. L., J. C. Kwong, S. L. Deeks, M.A.Campitelli, F.B. Jamieson, A. Marchand- Austin, T.A. Stukel, L. Rosella, N. Daneman, S. Bolotin, S.J. Drews, H. Rilkoff, and N. S. Crowcroft. 2016. “Effectiveness of Pertussis Vaccination and Duration of Immunity.” Canadian Medical Association Journal 188(16): E399–E406. https://doi.org/10.1503/cmaj.160193.

Serum Institute of India PVT, Ltd. 2023. “R21/Matrix-M™ Malaria Vaccine Developed by University of Oxford Receives Regulatory Clearance for Use in Ghana.” https://www.seruminstitute.com/press_release_sii_130423.php (accessed 3 June 2023).

Stengers, Isabelle. 2005. “The Cosmopolitical Proposal.” In Making Things Public: Atmospheres of Democracy, Bruno Latour, ed. 994–1003. Cambridge, MA: MIT Press.

University of Oxford. 2023. “R21/Matrix-M™ Malaria Vaccine Developed by University of Oxford Received Regulatory Clearance for use in Ghana.” https://www.ox.ac.uk/news/2023-04-13-r21matrix-m-malaria-vaccine-developed-university-oxford-receives-regulatory (accessed 3 June 2023).

Vural, I. E., Matthew Herder and Janice E. Graham. 2021. “From Sandbox to Pandemic: Agile Reform of Canadian Drug Regulation.” Health Policy 125 (9): 1115–1120. https://doi.org/10.1016/j.healthpol.2021.04.018.

Wexler, Mark K. 2009. “Exploring the Moral Dimension of Wicked Problems.” International Journal of Sociology and Social Policy 2919(10): 531–542. https://doi.org/10.1108/01443330910986306.

World Health Organization. 2005. “International Health Regulations.” World Health Organization, 1 January. https://www.who.int/publications/i/item/9789241580410. (accessed 3 June 2023).

——. 2013. “Malaria Vaccine Technology Roadmap.” World Health Organization, 5 November. https://www.who.int/publications/m/item/malaria-vaccine-technology-roadmap. (accessed 3 June 2023).

——. 2016. “WHO Welcomes Global Health Funding for Malaria Vaccine.” World Health Organization, 17 November. http://www.who.int/en/news-room/detail/17-11-2016-who-welcomes-global-health-funding-for-malaria-vaccine (accessed 3 June 2023).

——. 2020. Malaria: “The Malaria Vaccine Implementation Program (MVIP).” World Health Organization, 2 March. https://www.who.int/news-room/questions-and-answers/item/malaria-vaccine-implementation-programme (accessed 3 June 2023).

——. 2021. “Vaccine Efficacy, Effectiveness and Protection.” World Health Organization, 14 July. https://www.who.int/news-room/feature-stories/detail/vaccine-efficacy-effectiveness-and-protection (accessed 3 June 2023).

——. 2023a. “The Access to COVID-19 Tools (ACT) Accelerator.” World Health Organization. https://www.who.int/initiatives/act-accelerator. (accessed 3 June 20230.

——. 2023b. “Malaria.’ World Health Organization, 4 December. https://www.who.int/news-room/fact-sheets/detail/malaria. (accessed 3 June 2023).

Zeng, Wu, Y.-A. Halasa-Rappel, N. Baurin, L. Coudeville, and D. Shepard. 2018. “Cost- Effectiveness of Dengue Vaccination in Ten Endemic Countries.” Vaccine 3(3): 413–420. https://doi.org/10.1016/j.vaccine.2017.11.064.

Zimmer, Carl and Keith Collins. 2021. “What do vaccine efficacy numbers actually mean?” New York Times, 3 March. https://www.nytimes.com/interactive/2021/03/03/science/vaccine-efficacy-coronavirus.html (accessed 3 June 2023).